Luomalla maksuttoman Inderes-tilin, pääset käsiksi Inderesin analyysiin, voit tilata suositun aamukatsauksen ja seurata sinua kiinnostavia yhtiöitä sekä keskusteluita.
Onko sinulla jo Inderes-tili?
Follow this company like 1323 other investors.
Redeyes view on the Q2 report. With a powerful report and above our estimates, we adjust our forecasts for the rest of the current year. We increase our Base case to SEK 370 (340) and fair value range to SEK 230 – 520 (220 – 490) per share.
Redeyes view on the Q1 report. With a report slightly above our estimates, we only make minor adjustments to our forecasts for the current year. We leave our Base case at SEK 340 unchanged.
Redeyes view on the Q4 report. We make minor adjustments to our estimates for 2022, with a slightly lower growth assumption. We adjust our Base case to SEK 340 (330) per share with an unchanged fair value range.
Redeyes's first comments on the Q4 report earlier this morning.
Redeyes's first comments on the Q3 report earlier this morning.
Redeye views the Q2 from Cellavision this morning as very much in line with our expectations and continued solid recovery story.
Redeye’s first comments on CellaVision’s report for Q1’21. The report showed stronger sales than we expected at SEK 134m vs. our SEK 123m, a flat development compared to last year.